Comparative efficacy and safety of immunotherapies targeting PD-1/PD-L1 pathway for previously treated advanced non-small cell lung cancer: Bayesian network meta-analysis.

被引：1
|
作者：
Almutairi, Abdulaali
Alsaid, Nimer
Martin, Jennifer
Babiker, Hani M.
McBride, Ali
Abraham, Ivo
机构：
[1] Univ Arizona, Coll Pharm, Tucson, AZ 85721 USA
[2] Univ Arizona, Ctr Canc, Tucson, AZ USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.e21012
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e21012
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Comparative efficacy and safety of immunotherapies targeting the PD-1/PD-L1 pathway for previously treated advanced non-small cell lung cancer: A Bayesian network meta-analysis
    Almutairi, Abdulaali R.
    Alkhatib, Nimer
    Martin, Jennifer
    Babiker, Hani M.
    Garland, Linda L.
    McBride, Ali
    Abraham, Ivo
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2019, 142 : 16 - 25
  • [2] Comparative efficacy and safety of PD-1/PD-L1 immunotherapies for non-small cell lung cancer: a network meta-analysis
    Wang, D-D
    Shaver, L. G.
    Shi, F-Y
    Wei, J-J
    Qin, T-Z
    Wang, S-Z
    Kong, Y. J.
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2021, 25 (07) : 2866 - 2884
  • [3] PD-1 versus PD-L1 inhibitors for previously treated advanced non-small cell lung cancer (NSCLC): Bayesian network meta-analysis (NMA).
    Almutairi, Abdulaali
    McBride, Ali
    Garland, Linda L.
    Abraham, Ivo
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [4] Efficacy and safety of PD-1/PD-L1 inhibitors in elderly patients with advanced non-small cell lung cancer
    Li, Li
    Xu, Chunhua
    Wang, Wei
    Zhang, Qian
    CLINICAL RESPIRATORY JOURNAL, 2024, 18 (05):
  • [5] Targeting the PD-1/PD-L1 axis in non-small cell lung cancer
    Kumar, Rajiv
    Collins, Dearbhaile
    Dolly, Saoirse
    McDonald, Fiona
    O'Brien, Mary E. R.
    Yap, Timothy A.
    CURRENT PROBLEMS IN CANCER, 2017, 41 (02) : 111 - 124
  • [6] The efficacy and safety of PD-1/PD-L1 inhibitors versus chemotherapy in patients with previously treated advanced non-small-cell lung cancer A meta-analysis
    Wu, Lin-guang-jin
    Zhou, Dan-ni
    Wang, Ting
    Ma, Jun-zhi
    Sui, Hua
    Deng, Wan-li
    MEDICINE, 2021, 100 (12) : E25145
  • [7] Efficacy and safety of the PD-1/PD-L1 in metastasic non-small cell lung cancer (NSCLC)
    Gonzalez-Velez, Abel
    Pino-Villareal, Luis E.
    Barrera-Barinas, Alexander
    Castillo-Niuman, Andrea
    Tolosa-Perez, Erica N.
    Castelblanco, Diana, I
    Pinzon-Florez, Carlos E.
    Yomayusa, Nancy
    GACETA MEXICANA DE ONCOLOGIA, 2021, 20 (03): : 111 - 123
  • [8] Efficacy and Safety of PD-1/PD-L1 Inhibitors Plus Chemotherapy Versus PD-1/PD-L1 Inhibitors in Advanced Non-Small Cell Lung Cancer: A Network Analysis of Randomized Controlled Trials
    Li, Xiang
    Yan, Shi
    Yang, Jichun
    Wang, Yaqi
    Lv, Chao
    Li, Shaolei
    Zhao, Jun
    Yang, Yue
    Zhuo, Minglei
    Wu, Nan
    FRONTIERS IN ONCOLOGY, 2021, 10
  • [9] Comparative efficacy and safety of first-line PD-1/PD-L1 inhibitors in immunotherapy for non-small cell lung cancer: A network meta-analysis
    Liu, Liyan
    Yan, Yilong
    Wang, Yuqiao
    Li, Ziming
    Yang, Li
    Yu, Kefu
    Zhao, Zhigang
    ONCOLOGY LETTERS, 2025, 29 (03)
  • [10] Impact of Clinicopathological Features on the Efficacy of PD-1/PD-L1 Inhibitors in Patients with Previously Treated Non-Small Cell Lung Cancer
    Jiang, T.
    Qiao, M.
    Zhou, C.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2419 - S2419
12345